Q-omics provides the consensus-scored OPCML-IT2 profile across patient tissues and cancer cell-line models. OPCML-IT2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, OPCML-IT2 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, OPCML-IT2 RNA expression shows 10,514 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THYM, BRCA, and GBM as cancer lineages where OPCML-IT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPCML-IT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPCML-IT2 survival associations across molecular data types. OPCML-IT2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPCML-IT2 RNA expression–survival associations across cancer types. High OPCML-IT2 expression shows unfavorable associations in THYM, CESC, KICH, OV, LUSC and KIRP. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for OPCML-IT2 RNA expression.
This table summarizes OPCML-IT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OPCML-IT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPCML-IT2 shows higher tumor expression in BRCA. The BRCA box plot shows higher OPCML-IT2 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .048).
This table shows molecular features associated with OPCML-IT2 in patient tissues and cancer cell lines. In patient samples, OPCML-IT2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
